Gold Falls 3%; Carter's Shares Gain After Q3 Earnings

Global equities traded higher, with U.S. indices gaining over 0.5% and positive closes across European and Asian markets. Carter's Inc. reported mixed Q3 results, beating EPS but missing sales, and projected a significant $200M-$250M annualized pre-tax earnings impact from new tariffs. Individual stock highlights included Sotherly Hotels surging over 130% on an acquisition agreement, while Intellia Therapeutics plummeted 43% after halting patient dosing in Phase 3 clinical trials, and Organon & Co. fell 20% following its CEO's resignation amid an investigation.

Analysis

U.S. equities experienced broad gains, with the Dow Jones, NASDAQ, and S&P 500 rising 0.51%, 1.68%, and 1.01% respectively. This positive sentiment extended globally, as European and Asian markets also closed higher. Communication services led sector gains with a 1.5% increase, while utilities declined by 0.4%.

Carter's Inc. (CRI) shares advanced 5% following its Q3 earnings report, which saw EPS of $0.74 beat the $0.73 consensus. However, the company missed sales estimates, reporting $757.836 million against a $769.763 million forecast. Critically, Carter's projects a substantial $200 million to $250 million annualized gross pre-tax earnings hit from new administration tariffs, a significant increase from $110 million in FY2024 duties.

Significant M&A activity drove Sotherly Hotels Inc. (SOHO) shares up 137% on an acquisition agreement. Co-Diagnostics, Inc. (CODX) surged 102% after securing a definitive agreement for a Middle East expansion. BIO-key International, Inc. (BKYI) also saw a 115% increase following a strategic partnership in Scandinavia.

Conversely, Intellia Therapeutics, Inc. (NTLA) plummeted 43% after halting patient dosing in its MAGNITUDE Phase 3 clinical studies. Organon & Co. (OGN) shares fell 20% due to CEO Kevin Ali's resignation amid an Audit Committee investigation. Genenta Science S.p.A. (GNTA) also dropped 43% following the pricing of a $15.0 million registered direct offering.

Key Decisions for Investors

• Investors should closely monitor Carter's Inc.'s ability to mitigate the projected $200M-$250M annualized tariff impact, as this significantly outweighs the Q3 EPS beat and could pressure future profitability.
• Given Intellia Therapeutics' (NTLA) sharp decline, investors in the biotech sector should re-evaluate clinical trial stage assets for potential similar halts and their severe stock price implications.
• Consider opportunities in companies like Sotherly Hotels (SOHO), Co-Diagnostics (CODX), and BIO-key (BKYI) that demonstrate significant value creation through M&A or strategic international expansion.
• Exercise caution with companies like Organon (OGN) facing leadership changes due to investigations, and Genenta Science (GNTA) undergoing direct offerings, as these events signal potential governance issues or dilution risks.